期刊
FUTURE NEUROLOGY
卷 15, 期 4, 页码 -出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fnl-2020-0012
关键词
cariprazine; D3 receptor; dopamine; negative symptoms; partial agonist; schizophrenia
资金
- Janssen
- Allergan
- Angelini
- Boheringer Ingelheim
- Daiichi Sankyo Brasil Farmaceutica, Doc Generici
- Pfizer
- Sanofi Aventis
- Sunovion - Recordati
- Takeda
- Doc Generici
- FB-Health
- Italfarmaco
- Lundbeck
- Mylan
- Otsuka
- Recordati
- Sunovion
- Vifor
In schizophrenia, dopaminergic hyperactivity in the mesolimbic regions, or possibly even selectively so in the dorsal striatum, seems to cause the emergence of psychotic symptoms, whereas dopaminergic hypoactivity in cortical regions underlies the negative symptoms and cognitive deficits. Managing the negative symptoms is a major current challenge in the treatment of schizophrenia with a dearth of novel modalities to address this clinical issue. Cariprazine is a novel second-generation antipsychotic that specifically targets the D3 receptor mainly associated to negative symptoms. The review summarizes the main issues regarding negative symptom management and the role of cariprazine treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据